FDA Narrows Menopause Hormone Therapy’s Boxed Warning

Menopausal hormone therapy labelingWhat to know

30-second read

For OB/GYN · Family Medicine · Internal Medicine

Who

Patients on, or candidates for, estrogen-containing menopausal hormone therapy — patches, gels, tablets, rings — especially those under 60 or within 10 years of menopause.

What changed

FDA stripped cardiovascular-disease, breast-cancer and “probable dementia” boxed-warning text from 3 more estradiol patches on Oct 30, 2026; 9 products relabeled since Feb.

Evidence

No new trial data: a 2-hour July 2025 FDA panel, not a formal advisory committee, re-read the 2002 WHI data through a “start before 60 or within 10 years” lens.

What it adds

Two camps are now disputing this in JAMA — FDA leadership says the old label overstated risk; former WHI safety monitors say the change outruns the evidence.

Key consideration

FDA won’t name the 3 patches that changed Oct 30. The endometrial-cancer warning stays for estrogen-alone therapy in a patient with a uterus.

Access

All 9 products were already FDA-approved and on the market; this changes labeling, not availability. An OTC switch for patches is separately under FDA review.

Practice impactVerify the label, don't assume

A narrower warning is not new efficacy or safety data, and respected trialists are now publicly disputing the change in JAMA. Counsel from the patient and the specific product's current label — not a headline about boxed warnings.

Read the full physician analysis

Full analysis · 9 min readFDA/HHS, Oct 30 2026 · JAMA (Makary; Wittes et al.) · DailyMed

FDA and HHS approved updated labeling for three more estradiol transdermal patches on October 30, 2026, stripping cardiovascular-disease, breast-cancer and “probable dementia” language from the products' boxed warnings. It is the second round of a rollback that began in February and now covers nine menopausal hormone therapy (MHT) products. What it does not cover: the agency has not named which three patches changed, and the science behind the broader rollback is now the subject of a public dispute in JAMA between FDA leadership and a group of former Women's Health Initiative (WHI) safety monitors.

What changed in the box — and what FDA won't say

The boxed warning at issue dates to 2003, added across the MHT class after the original WHI findings linked certain hormone regimens to cardiovascular disease and breast cancer, with a later WHI Memory Study (WHIMS) finding adding “probable dementia” language for women who started therapy after age 65. HHS and FDA announced in November 2025 that they would revisit that warning, and approved the first concrete labeling changes on February 12, 2026, for six products spanning all four MHT categories: progestogen-only (Prometrium), systemic estrogen-alone (Divigel), combined systemic estrogen-progestogen (Bijuva), and topical vaginal estrogen (Estring, Cenestin, Enjuvia). The October 30 action extends the same change to three more products — estradiol transdermal patches, from two applicants — bringing the total to nine.

Here is the detail that matters most for a prescribing decision this week: neither FDA nor HHS has named the three patches. Reuters reported that HHS did not respond to a request for the brand names; Contemporary OB/GYN and other outlets covering the October 30 release independently confirm that the agency gave no product or manufacturer detail beyond “estradiol transdermal patches from two applicants.” That means a physician cannot tell from this announcement alone whether a specific patient's patch carries the revised label or the pre-2026 one — the only way to know is to check that product's current labeling directly, on DailyMed or the product's own package insert. The prior boxed-warning language is not deleted for covered products; it remains available lower in the label, just without the prominent boxed framing.

The evidence behind the rewrite

FDA's published rationale is a JAMA viewpoint from Commissioner Marty Makary, published online December 5, 2025. Its core argument: the WHI trials that produced the original warning enrolled women with a mean age in their early 60s, many more than a decade past menopause, and did not require — or test — starting therapy before age 60 or within 10 years of menopause onset, the window more recent analyses associate with the most favorable cardiovascular risk profile. On that reading, a boxed warning built from an older, later-starting population overstated the risk for a younger, earlier-starting one, and the label should say so.

That case was built on existing data, not a new trial. The process FDA used to weigh it was a roughly two-hour expert panel convened July 17, 2025 — not one of FDA's standing advisory committees, which meet publicly with broader membership and a formal comment record. Following the panel, 29 companies submitted proposed labeling changes at FDA's request; nine products across two rounds have cleared so far, with the remainder still under review.

A dispute breaks out in JAMA

The rewrite has not gone unanswered. In April 2026, JAMA published “Menopausal Hormone Labels Should Rely on Evidence, Not Opinion,” a viewpoint from biostatistician Janet Wittes, cardiologist Eugene Braunwald and several co-authors, a number of whom served on WHI's data and safety monitoring board. Their argument, as described in the piece's own framing: the label change extrapolates beyond what the WHI and subsequent analyses actually established, and a policy change of this scale deserved the fuller, more public scrutiny of a formal advisory committee rather than an invited panel. WHI's own research organization has reinforced a related, narrower point on its website: the trial did not test transdermal or vaginal formulations of hormone therapy at all, and its investigators continue to recommend against using oral MHT for chronic-disease prevention — a use case distinct from treating menopausal symptoms.

A second line of criticism concerns the July 2025 panel itself rather than the data. Public Citizen and other commentators have noted that the invited panelists were drawn overwhelmingly from clinicians and researchers already publicly supportive of expanded hormone-therapy use, with some tied to a hormone-therapy advocacy campaign backed by pharmaceutical sponsors. FDA has not disputed the panel's composition; its position is that the panel's purpose was expert consultation on a labeling update, not a formal advisory committee vote, and that the agency's own literature review drove the decision. None of this is settled science either way — it is an active, public disagreement among researchers who all worked from the same underlying trial, and Regulatory News is reporting the dispute, not adjudicating it.

What the boxed warning covered, before and after

	Pre-2026 boxed warning	Current labeling (9 relabeled products)
Cardiovascular disease	In the boxed warning, class-wide	Moved out of the boxed warning; remains lower in labeling
Breast cancer	In the boxed warning, class-wide	Moved out of the boxed warning; remains lower in labeling
“Probable dementia”	In the boxed warning (WHIMS-derived)	Moved out of the boxed warning; remains lower in labeling
Endometrial cancer	In the boxed warning for estrogen-alone systemic products	Unchanged — still in the boxed warning
Progestin pairing guidance	For estrogen-alone use in a patient with a uterus	Unchanged — still advised

Applies to the nine products FDA has confirmed relabeled across the February and October 2026 rounds. Any product not confirmed on this list — including, as of this writing, the three October patches — should be assumed to carry the prior labeling until checked directly.

What this does, and doesn't, change for a patient in your chair

ACOG welcomed the broader rollback, and its leadership has specifically credited it with removing a barrier to prescribing low-dose vaginal estrogen for genitourinary symptoms of menopause — a formulation ACOG says the old boxed warning discouraged clinicians from using even though its systemic absorption, and therefore its systemic risk, is minimal. That is a real, usable practice change: a patient with vaginal dryness, dyspareunia or recurrent UTIs tied to genitourinary syndrome of menopause is now reading a less alarming label on a product with a well-established local safety profile. But ACOG's own then-immediate-past president was explicit on the broader point: the organization's clinical guidelines are not changing because the boxed warning changed. The label rewrite does not, by itself, establish that systemic therapy is safe to start later in life, does not add new indications, and does not resolve the active dispute over how to apply the timing hypothesis in an individual patient.

Practically, that leaves three separate judgment calls that this labeling round does not make for you. First, patient selection: the strongest case for reassurance remains a patient under 60 or within 10 years of menopause with bothersome vasomotor or genitourinary symptoms and no contraindication — not a blanket case for broader use across all ages. Second, route and formulation still matter clinically even though this round's boxed-warning text does not distinguish them in detail; WHI itself notes it never tested transdermal or vaginal routes directly, so route-specific risk conversations should still draw on the product's full labeling and the broader observational literature, not the boxed-warning headline alone. Third, reimbursement and access are untouched: this is a labeling action, not a coverage decision, and formulary placement, prior authorization and cost-sharing for any of the nine products are whatever they already were before October 30.

• Check the specific product, not the headline. Confirm on DailyMed or the current package insert whether a patient's exact brand is among the nine relabeled products — FDA has not named the three October patches.
• Keep the endometrial-cancer warning and progestin-pairing guidance in the conversation for any estrogen-alone systemic product in a patient with a uterus; nothing here changed that.
• Use the vaginal-estrogen label change where it's most clearly actionable — genitourinary symptoms in a patient who was previously deterred by boxed-warning language on a low-systemic-absorption product.
• Don't read a narrower box as new trial evidence. Base a systemic-therapy initiation decision on the patient's age, time since menopause, symptom burden and individual risk factors, the same inputs timing-hypothesis guidance already called for — and be ready to discuss the ongoing JAMA dispute with a patient who has read about it.
• Coverage is a separate question. This round changed labeling, not formulary status, prior-authorization rules or cost-sharing for any product.

How the rollback got here, and what's still open

1. 2002–03

   WHI findings, original boxed warning

   WHI trial results on combined and estrogen-alone therapy lead to the class-wide boxed warning; a later WHIMS analysis adds dementia language for later-starting patients.

2. Jul 17, 2025

   FDA expert panel

   A roughly two-hour invited panel, not a formal advisory committee, reviews the warning; critics later note most panelists were already supportive of expanded use.

3. Nov 10, 2025

   HHS/FDA announce the rollback

   The agencies say they will remove the broad cardiovascular, breast-cancer and dementia boxed-warning language across MHT products, citing the literature review and panel.

4. Dec 5, 2025

   Makary's JAMA viewpoint

   FDA's rationale is published: the original trials didn't test starting therapy before 60 or within 10 years of menopause.

5. Feb 12, 2026

   Round 1: six products relabeled

   Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva receive updated labeling.

6. Mar 23, 2026

   A clinician's-eye JAMA viewpoint

   Deborah Bartz and colleagues frame the change as both an opportunity and a challenge for prescribers.

7. Apr 14, 2026

   Wittes/Braunwald response in JAMA

   Former WHI safety monitors argue the label change runs ahead of the evidence.

8. Oct 30, 2026

   Round 2: three more patches relabeled

   Two applicants' estradiol patches are updated; FDA does not name them.

9. Ahead

   More of 29 submissions pending; OTC review separate

   Additional products among the 29 that submitted changes remain under review; FDA is separately weighing, not deciding, an OTC switch for estradiol patches.

Frequently asked questions

Which three estradiol patches changed on October 30, 2026?

FDA and HHS have not said. Multiple outlets asked for the brand names at the time of the announcement and none were given; coverage agrees only that the three products are estradiol transdermal patches from two applicants. Check a specific patient's product directly on DailyMed rather than assuming any particular brand is or is not covered.

Does this mean hormone therapy is now proven safer than the 2002 Women's Health Initiative found?

No new trial data accompanies this label change. FDA's rationale, laid out in a JAMA viewpoint by Commissioner Marty Makary, is that the original WHI trials did not test starting therapy before age 60 or within 10 years of menopause — the window current thinking says carries the most favorable risk profile — so the old boxed warning overstated risk for that population. A subsequent JAMA viewpoint from Janet Wittes, Eugene Braunwald and other former WHI safety monitors argues the label change outruns the evidence. Both sides are arguing about how to interpret existing data, not presenting new trial results.

Has ACOG or another professional society changed its guidance because of this?

No. ACOG's then-immediate-past president said explicitly that the organization's own clinical guidelines are not changing because the boxed warning was removed. ACOG did welcome the change — it has separately argued the warning discouraged appropriate use of low-dose vaginal estrogen — but has also pushed FDA to use a full advisory committee process rather than the smaller panel it convened.